相关实验视频
Updated: May 22, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.2K
决策辅助不是改善晚期帕金森病共享决策的快速解决方案:混合方法可行性研究的结果
Frouke A P Nijhuis1,2, Bas Schippers3, Bastiaan R Bloem3
1Department of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. f.nijhuis@cwz.nl.
Journal of neurology
|March 13, 2025
概括
这项研究评估了对选择设备辅助治疗的帕金森病患者的共享决策 (SDM) 干预. 虽然可以接受并改善知识,但干预并没有像预期的那样增强SDM.
科学领域:
- 神经学 神经学
- 医疗决策的制定 医疗决策的制定
- 医疗保健服务研究 医疗服务研究
背景情况:
- 为帕金森病 (PD) 选择设备辅助治疗方法是复杂的.
- 一个共享决策 (SDM) 干预措施被开发来帮助这个过程.
- 这项研究从患者的角度评估了SDM干预的可行性.
研究的目的:
- 评估共享决策 (SDM) 对帕金森病患者 (PwPD) 的干预措施的可行性.
- 评估患者接受度,实施水平和SDM干预的有效性.
- 确定在临床实践中使用SDM干预措施的障碍和促进因素.
主要方法:
- 多中心,混合方法可行性研究,采用不受控制的干预前后设计.
- 涉及5家荷兰医院的神经科医生和帕金森病专家护士.
- 包括患者决策辅助和专业培训;通过问卷,访谈和使用日志收集的数据.
主要成果:
- 包括19名常规护理组的参与者和13名干预组的参与者.
- SDM干预表现出良好的接受度,92%的参与者使用了患者决策辅助工具.
- 虽然改善了患者对治疗选择的了解,但该干预措施并没有显著提高共享决策 (SDM).
结论:
- 该研究的患者招募有限.
- 患者可以接受SDM干预,但未按预期使用,表明需要更好地整合到临床工作流程中.
- 建议加强医生与使用患者决策辅助工具的患者之间的合作,以改善SDM.
相关概念视频
Parkinson's Disease: Treatment
174
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
174
Parkinson's Disease: Overview
410
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
410
Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141

